ASCO: Everolimus Reverses Resistance to Other Therapies

posted on Jun 07 by MedPage Today OB/Gyn in the Uncategorized category CHICAGO (MedPage Today) -- Researchers said here that by adding the targeted agent everolimus (Afinitor) to the regimen of women whose advanced breast cancer is no longer sensitive to paclitaxel (Taxol) and trastuzumab (Herceptin), it appears that the resistance can be switched off and response rates enhanced.